Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30673283 | 1.00 | ACP1 (0.42) | ACP1CHRNB4CHRNA3TSHRHTT | |
| SCHEMBL28421376 | 0.87 | ACP1 (0.43) | ACP1CHRNB4CHRNA3TSHRHTT | |
| SCHEMBL11273785 | 0.87 | CYP19A1 (0.50) | TSHRHTTPOLBCYP19A1ALOX5 | |
| SCHEMBL5944012 | 0.82 | F2RL3 (0.39) | ACP1CHRNB4CHRNA3TSHRHTT | |
| SCHEMBL8570170 | 0.81 | HTT (0.48) | ACP1CHRNB4CHRNA3TSHRHTT | |
| SCHEMBL18538952 | 0.80 | HTT (0.47) | TSHRHTTPOLBCYP19A1ALOX5 | |
| SCHEMBL602087 | 0.79 | ACP1 (0.42) | ACP1CHRNB4CHRNA3TSHRHTT | |
| SCHEMBL29735419 | 0.79 | ACP1 (0.42) | ACP1CHRNB4CHRNA3TSHRHTT | |
| SCHEMBL2504040 | 0.79 | ACP1 (0.36) | ACP1CHRNB4CHRNA3TSHRHTT | |
| SCHEMBL18545294 | 0.79 | TSHR (0.51) | TSHRHTTPOLBCYP19A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4518974-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023239941-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239941-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8722687-B2 | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy | ASTEX THERAPEUTICS LTD (GB) | 2014-05-13 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | ACP1 224/4885CHRNB4 2662/4885CHRNA3 3259/4885 |
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | FGFR1, FGFR3, FGFR2 | ACP1 622/4885CHRNB4 4759/4885CHRNA3 4402/4885 |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | ACP1 550/4885CHRNB4 4503/4885CHRNA3 3917/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | ACP1 224/4885CHRNB4 2662/4885CHRNA3 3259/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | ACP1 224/4885CHRNB4 2662/4885CHRNA3 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.